Works by Kok, Victor C


Results: 38
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32

    Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens

    Published in:
    Breast Cancer Research & Treatment, 2021, v. 189, n. 3, p. 665, doi. 10.1007/s10549-021-06313-5
    By:
    • Dai, Ming Shen;
    • Feng, Yin Hsun;
    • Chen, Shang Wen;
    • Masuda, Norikazu;
    • Yau, Thomas;
    • Chen, Shou Tung;
    • Lu, Yen Shen;
    • Yap, Yoon Sim;
    • Ang, Peter C. S.;
    • Chu, Sung Chao;
    • Kwong, Ava;
    • Lee, Keun Seok;
    • Ow, Samuel;
    • Kim, Sung Bae;
    • Lin, Johnson;
    • Chung, Hyun Cheol;
    • Ngan, Roger;
    • Kok, Victor C.;
    • Rau, Kun Ming;
    • Sangai, Takafumi
    Publication type:
    Article
    33
    34
    35
    36
    37
    38